Novavax, Inc. (NVAX)

Novavax Revenue by Segment

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021
Product	729.79M	190.44M	391.89M	355.91M	621.17M	531.39M	567.72M	1.19B
Product Growth	17.49%	-64.16%	-30.97%	-70.13%	-35.42%	-65.83%	-55.20%	85.87%
Licensing Royalties and Other	525.86M	492.41M	455.36M	428.89M	35.50M	24.99M	23.09M	5.47M
Licensing Royalties and Other Growth	1,381.50%	1,870.20%	1,872.54%	7,747.96%	36.64%	-43.18%	-86.51%	-97.43%
Grants	-	-	-	-	-	427.32M	458.95M	400.30M
Grants Growth	-	-	-	-	-	11.60%	12.39%	-8.41%

Revenue by Geography

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022
North America	110.79M	65.02M	56.94M	25.21M	23.60M	29.96M	2.23M	-
North America Growth	369.51%	117.04%	2,452.35%	-	-	-	-	-
Rest of World	76.94M	31.92M	33.62M	30.55M	296.06M	233.07M	-	593.28M
Rest of World Growth	-74.01%	-86.30%	-	-94.85%	-18.91%	-56.59%	-	-
Europe	10.94M	93.27M	301.33M	300.16M	301.51M	268.36M	-	468.58M
Europe Growth	-96.37%	-65.24%	-	-35.94%	-35.45%	-67.41%	-	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.